SLC5A2 and hydrops fetalis: In all trials, SGLT2 inhibitors significantly reduced the risk of hospitalization for HF with large effect size (HR, 0.68; 95% CI, 0.62–0.75; p < 0.001) and no heterogeneity (I2 = 5%; p = 0.92) (Supplementary Fig. 3).